CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM	*Assay*	*USP36–NF31*	4838	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CHLORIDE EX TENDED-RELEASE CAPSULES								*Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution.
SELEGILINE HYDROCHLORIDE TABLETS	*Dissolution <711>*	*USP36–NF31*	5120	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Chromatographic system*: Change Chromatograph the *Standard solution*, and record the peak responses. to: The flow rate is 1.0 mL/min. Chromatograph the *Standard solution*, and record the peak responses.
BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS	METHODOLOGIES OF AMINO ACID ANALYSIS GENERAL PRINCIPLES	*USP36–NF31*	619	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change the section title *Method 6—Postcolumn DABS-Cl Derivatization General Principle* to: *Method 6—Precolumn DABS-Cl Derivatization*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VERAPAMIL HYDROCHLORIDE ORAL SUSPENSION	*Assay*	*USP36–NF31*	5558	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	*General Principle* Line 2 of *Mobile phase*: Change 0.01 M to: 0.01 N AND Line 7 of *Assay preparation*: Change 10-mL to: 100-mL
AMITRIPTYLINE HYDROCHLORIDE TABLETS	IDENTIFICATION/*A*.	*USP36–NF31*	2464	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Sample solution*: Nominally 0.01 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate for analysis. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Sample stock solution: Nominally 0.1 mg/mL of amitriptyline hydrochloride in methanol from a suitable amount of finely powdered Tablets. Filter a portion of the solution, and use the filtrate. *Sample solution*: Nominally 0.01 mg/mL of amitriptyline hydrochloride from *Sample stock solution* in methanol
MINOCYCLINE FOR INJECTION	*Assay*	*USP36–NF31*	4375	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Mobile phase*, *Standard preparation*, *Resolution solution*, and *Chromatographic*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								system—Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer porosity. Make adjustments if necessary (see *System Suitability* under *Chromatograph*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								y <621>). *Standard prep aration* —Dissolve an accurately weighed quantity of USP Minocycline Hydrochloride RS in water to obtain a solution having a known concentration of about 500 µg of minocycline ($C_{23}H_{27}N_3O_7$) per mL. Use this solution within 3 hours. *Resolution solution* —Transfer 10 mg of USP Minocycline Hydrochloride RS to a 25-mL volumetric flask, add 20 mL of 0.2 M

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ammonium oxalate, and swirl to dissolve. Heat on a water bath at 60° for 180 minutes, and allow to cool. Dilute with water to volume, and mix. *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								about 1.5 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								directed for *Procedure*: the relative retention times are about 0.7 for epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
OXYCODONE AND ACETAMINOPHEN TABLETS	IDENTIFICATION/*A. Thin-Layer Chromatography*	*USP36–NF31*	4645	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Sample solution*: Change in a mixture of methanol and water (4:1). to: in a 5-mL mixture of methanol and water (4:1).
POTASSIUM BICARBONATE AND POTASSIUM CHLORIDE EFFERVESCENT TABLETS FOR	*Assay for potassium*	*USP36–NF31*	4834	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL SOLUTION								*Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM CHLORIDE EXTENDED-RELEASE TABLETS	*Assay*	*USP36–NF31*	4841	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution* and *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparations—to: *Standard stock solution* and *Standard solutions*—Line 1 of *Procedure*: Change in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*, except use *Assay preparation 1* or *Assay preparation 2* instead of *Sample solution*.
ISOTRETINOIN CAPSULES	PERFORMANCE	*Revision Bulletin (Official*	Online	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2 of *Medium*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	TESTS/ *Dissolution <711>/Test 4*	*October 01, 2012)*						Change 4.5% (v/v) of Milloxid L (lauryl dimethyl amine oxide) to: 4.5% (v/v) of lauryl dimethyl amine oxide
TROLAMINE SALICYLATE	*Assay*	*USP36–NF31*	5499	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Chromatographic system*: Change L1 to: L7
NITRIC ACID	ASSAY/ *Procedure*	*USP36–NF31*	2107	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample solution*: Change To 2 mL of Nitric Acid in a tared, glass-stoppered conical flask add 25 mL of water. to: Weigh 2 mL of Nitric Acid in a glass-stoppered

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								conical flask, and add 25 mL of water.
FOSPHENYTOIN SODIUM INJECTION	*Assay*	*USP36–NF31*	3680	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Assay preparation*: Change Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin, to: Transfer an accurately measured volume of the Injection, equivalent to about 300 mg of fosphenytoin sodium,
MOXIFLOXACIN OPHTHALMIC SOLUTION	*Assay*	*USP36–NF31*	4414	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 4 of *Resolution solution*: Change 0.1 mg per mg and 0.001 mg per mg,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POTASSIUM BICARBONATE EFFERVESCENT TABLETS FOR ORAL SOLUTION	*Assay*	*USP36–NF31*	4833	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	to: 0.1 mg per mL and 0.001 mg per mL, Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under *Potassium Chloride Oral*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Solution, except use *Assay preparation* instead of *Sample solution*.
POTASSIUM CHLORIDE FOR ORAL SOLUTION	*Assay*	*USP36–NF31*	4840	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Potassium Chloride Oral Solution, except use *Assay preparation 1* or *Assay preparation 2* instead of *Sample solution*.
TACROLIMUS CAPSULES	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP36–NF31*	5257	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 11 of USP Tacrolimus System Suitability Mixture RS: Change and tacrolimus 8-propyl analog (3*S*,4*R*,5*S*,8*S*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-m

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ethoxycyclohexyl]-1-methylvinyl}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21-(4*H*,23*H*)-tetrone. to: and tacrolimus 8-propyl analog (3*S*,4*R*,5*S*,8*R*,9*E*,12*S*,14*S*,15*R*,16*S*,18*R*,19*R*,26a*S*)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(*E*)-2-[(1*R*,3*R*,4*R*)-4-hydroxy-3-methoxycyclohexyl]-1-methylvinyl

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								}-14,16-dimethoxy-4,10,12,18-tetramethyl-15,19-epoxy-8-propyl-3*H*-pyrido[2,1-*c*][1,4]oxaazacyclotricosine-1,7,20,21-(4*H*,23*H*)-tetrone.
BIOTECHNOLOGY-DERIVED ARTICLES—AMINO ACID ANALYSIS	APPENDIX	*USP36–NF31*	619	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Change the section title *Method 6—Postcolumn DABS-Cl Derivatization* to: *Method 6—Precolumn DABS-Cl Derivatization*
VITAMIN E	SPECIFIC TESTS/*Acidity*	*USP36–NF31*	5579	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample*: Change 40 mg to: 1.0 g
FOSPHENYTOIN SODIUM	*USP Reference standards <11>*	*USP36–NF31*	3679	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 6: Change $C_{14}H_{15}NO_2$ to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MINOCYCLINE HYDROCHLORIDE ORAL SUSPENSION	*Assay*	*USP36–NF31*	4376	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	$C_{14}H_{13}NO_2$ Line 2: Change *Mobile phase* and *Chromatographic system* —Proceed as directed in the *Assay* under *Minocycline Hydrochloride*. to: *Mobile phase*—Prepare a mixture of 0.2 M ammonium oxalate, 0.01 M edetate disodium, dimethylformamide, and tetrahydrofuran (600:180:120:80). Adjust with ammonium hydroxide to a pH of 7.2, and pass through a filter of 0.5-µm or finer pore

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								size. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 280-nm detector and a 4.6-mm × 25-cm column that contains 5-µm packing L1, and is maintained at a constant temperature of about 40°. The flow rate is about 1.5 mL per minute. Chromatograph the *Standard preparation*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and record the peak responses as directed for *Procedure*: the capacity factor, *k´*, is not less than 5.0 and not more than 11.5; the tailing factor for the analyte peak is not less than 0.9 and not more than 2.0; and the relative standard deviation for replicate injections is not more than 2.0%. Chromatograph the *Resolution solution*, and record the peak responses as directed for *Procedure*: the relative retention times are about 0.7 for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								epiminocycline and 1.0 for minocycline; and the resolution, *R*, between epiminocycline and minocycline is not less than 4.6. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Minocycline Hydrochloride*. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								record the chromatograms, and measure the responses for the major peaks.
OXYCODONE TEREPHTHALATE	ASSAY/ *Procedure*	*USP36–NF31*	4648	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 7 of *Analysis*: Change R_U = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the *Standard solution* R_S = internal standard ratio (peak response of oxycodone/peak response of ethylparaben) from the *Sample solution* to: R_U = peak response ratio of oxycodone to ethylparaben

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								from the *Sample solution* R_S = peak response ratio of oxycodone to ethylparaben from the *Standard solution*
POTASSIUM CHLORIDE EXTENDED-RELEASE CAPSULES	*Dissolution <711>*	*USP36–NF31*	4838	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 7 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								conditions and *Analysis* in the *Assay* under *Potassium Chloride Oral Solution*.
POTASSIUM CHLORIDE, POTASSIUM BI CARBONATE, AND POTASSIUM CITRATE EFFE RVESCENT TABLETS FOR ORAL SOLUTION	*Assay for potassium*	*USP36–NF31*	4843	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change *Potassium stock solution* and *Standard preparations*— to: *Standard stock solution* and *Standard solutions*— AND Line 1 of *Procedure*: Change for *Procedure* in the *Assay* under *Potassium Chloride Oral Solution*. to: for *Instrumental conditions* and *Analysis* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Potassium Chloride Oral Solution, except use *Assay preparation* instead of *Sample solution*.
ETHYLENE OXIDE AND DIOXANE	*Method II*	*USP36–NF31*	148	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 31 of *Analysis*: Change r_S = ethylene oxide peak responses from *Standard solution B* to: r_S = dioxane peak responses from *Standard solution B*
VERAPAMIL HYDROCHLORIDE ORAL SOLUTION	*Assay*	*USP36–NF31*	5558	31-May-2013	1-Jun-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Sodium acetate solution*: Change 0.01 M to: 0.01 N AND Line 6 of *Assay preparation*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATRACURIUM BESYLATE INJECTION	IM PURITIES/*Organic Impurities/Acceptance criteria/Table 2*	*Second Supplement to USP35–NF30*	5909	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Change 10-mL to: 100-mL Footnote b: Change *cis* isomer of the hydroxy compound. to: *trans* isomer of the hydroxy compound. AND Footnote c: Change *trans* isomer of the hydroxy compound. to: *cis* isomer of the hydroxy compound. AND Footnote d: Change *cis* isomer of the monoacrylate. to: *trans* isomer of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the monoacrylate. AND Footnote e: Change *trans* isomer of the monoacrylate. to: *cis* isomer of the monoacrylate.
ZINC SULFATE TABLETS	Identification/*B. Zinc*	*USP35–NF30*	5077	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sodium hydroxide solution*: Change 42 mg/mL of sodium hydroxide to: 420 mg/mL of sodium hydroxide
DIETHYL SEBACATE	DEFINITION	*USP36–NF31*	1994	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change Diethyl Sebacate consists of the diester of alcohol and sebacic acid.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: Diethyl Sebacate consists of the diester of alcohol (ethanol) and sebacic acid.
PROPYLENE GLYCOL MONOLAURATE	IM PURITIES/*Limit of Propylene Glycol*	*USP36–NF31*	2180	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 8 of *Analysis*: Change Calculate the percentage of free propylene glycol in the portion of Propylene Glycol Monocaprylate taken: to: Calculate the percentage of free propylene glycol in the portion of Propylene Glycol Monolaurate taken:
GLUCONOLAC	IDENTIFICATIO	*USP36–NF31*	3742	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 5 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TONE	N/*A.*							*Analysis*: Change crystals of the phenylhydrazine of gluconic acid to: crystals of the phenylhydrazide of gluconic acid
METHOTREXATE	IMPURITIES/*Organic Impurities*/*Procedure 1: Related Compounds*	*USP35–NF30*	3855	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Footnote b of *Impurity Table 1*: Change (*S*)-2-{4-[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methylamino]-*N*-methylbenzamido}pentanedioic acid. to: (*S*)-2-(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl](methyl)amino}benzami

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								do)pentanedioic acid.
BETAMETHASONE ORAL SOLUTION	*Identification/A:*	*USP35–NF30*	2336	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1: Change A: to: A: *Thin-Layer Chromatographic Identification Test* <201>—
VINORELBINE INJECTION	*Related compounds*	*USP35–NF30*	5028	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Delete the subsection *Standard solution* and *Diluted standard solution*. Replace with: *Standard solution* —Dissolve an accurately weighed quantity of USP Vinorelbine Tartrate RS in *Mobile phase* to obtain a solution having a known concentration of about 1.4 mg

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								per mL. *Diluted standard solution* —Transfer 1.0 mL of the *Standard solution* to a 50-mL volumetric flask, and dilute with *Mobile phase* to volume. Pipet 1.0 mL of this solution into a 100-mL volumetric flask, and dilute with *Mobile phase* to volume. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the test for *Related compounds* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Vinorelbine Tartrate. to: Separately inject equal volumes (about 20 µL) of the *Test solution* and the *Diluted standard solution* into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Record the chromatograms for three times the retention time of the vinorelbine peak. Disregard any peaks with an area less than or equal to one-half of the area of the peak obtained for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								vinorelbine in the *Diluted standard solution*. Calculate the percentage of each impurity in the portion of Injection taken by the formula: $100(r_i/r_s)$ in which r_i is the peak response for each impurity obtained from the *Test solution*; and r_s is the sum of the responses of all the peaks.
GOOD STORAGE AND DISTRIBUTION PRACTICES FOR DRUG PRODUCTS	QUALITY MANAGEMENT SYSTEM/*Storage Management System/Receiving and Transferring Drug Products*	*USP36–NF31*	693	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of footnote 1: Change JP Edmond, to: JP Emond,
HYDROGENAT	ASSAY/*Content*	*USP36–NF31*	2133	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ED POLYDECENE	*of Decene Oligomer*							*System suitability*: Change [Note—The retention time for squalene is about 18 min; the relative retention times for tetradecane, hexadecane, and squalene are about 0.5, 0.6, and 1.0, respectively.] to: [Note—The retention time for squalane is about 18 min; the relative retention times for tetradecane, hexadecane, and squalane are about 0.5, 0.6, and 1.0, respectively.]
CLOTRIMAZOLE AND BETAMETHASONE DI	ASSAY/ *Procedure*	*USP36–NF31*	3075	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 3 of *Betamethasone dipropionate*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PROPIONATE CREAM								*stock solution*: Change *J* being the ratio (in mg/g) of betamethasone to clotrimazole in the Cream to: *J* being the ratio of the labeled amount of betamethasone (in mg/g) to the labeled amount of clotrimazole (in mg/g) in the Cream
CALCIUM SULFATE	SPECIFIC TESTS/*Loss on Drying <731>*	*USP35–NF30*	1724	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Acceptance criteria*: Change NMT 1.5% for the anhydrous form and NMT 19.0%–23.0% for the dihydrate to: NMT 1.5% for the anhydrous form and 19.0%–23.0% for the dihydrate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TAPIOCA STARCH	*Limit of oxidizing substances*	*USP35–NF30*	1987	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 8: Change Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodide color. to: Add 1 mL of starch TS, and titrate with 0.002 N sodium thiosulfate VS to the disappearance of the starch–iodine color.
LEVETIRACETAM	ADDITIONAL REQUIREMENTS	*USP35–NF30*	3659	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 9 of *USP Reference Standards* <*11*>: Change $C_8H_{14}ClNO_3$ 207.65 to: $C_8H_{15}ClN_2O_2$ 206.67

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DULOXETINE DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*/ *Chromatographic system*	*Second Supplement to USP35–NF30*	5940	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Column*: Change 4.6-mm x 7.5-cm; 3-µm packing L7 to: 4.6-mm x 7.5-cm; 3- or 3.5-µm packing L7
HYMETELLOSE	IMPURITIES/*Chloride and Sulfate, Chloride <221>*	*USP36–NF31*	2044	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Change the subsection title *Standard solution* to: *Control solution* AND Line 4 of *Analysis*: Change *Standard solution* to: *Control solution* AND Line 2 of *Acceptance criteria*: Change *Standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Control solution*
BENZTROPINE MESYLATE	CHEMICAL INFORMATION	*USP36–NF31*	2628	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 2: Change 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-, *endo*-, methanesulfonate; to: 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-*N*-methyl-, *endo*-, methanesulfonate;
LORAZEPAM TABLETS	IMPURITIES/*Organic Impurities/System suitability/Suitability requirements*	*USP36–NF31*	4153	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Tailing factor*: Change 2.0, *Standard solution* to: NMT 2.0, *Standard solution*
BRINZOLAMIDE	*Related compounds/Test 2*	*USP35–NF30*	2385	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 15 of *Procedure*: Change relative retention time greater than 6. to: relative

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VINORELBINE INJECTION	*Assay*	*USP35–NF30*	5028	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	retention greater than 6. Line 1: Change *Phosphate buffer, Mobile phase,* and *System suitability solution* —Proceed as directed in the *Assay* under *Vinorelbine Tartrate*. to: *Phosphate buffer*—Dissolve 6.9 g of monobasic sodium phosphate in 900 mL of water. Adjust with phosphoric acid to a pH of 4.2, dilute with water to 1000 mL, and mix. *Mobile phase*—Dissolve 1.22 g of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sodium 1-decanesulfonate in 620 mL of methanol. Add 380 mL of *Phosphate buffer*, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography <621>*). *System suitability solution* —Dissolve accurately weighed quantities of USP Vinorelbine Tartrate RS and USP Vinorelbine Related Compound A RS in water, and dilute

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								quantitatively, and stepwise if necessary, with water to obtain a solution having known concentrations of about 1.4 mg per mL and 0.01 mg per mL, respectively. Expose a portion of this solution in a suitable xenon lamp apparatus capable of supplying a dose of 1600 KJ/m^2 between 310 and 800 nm at a power of 500 W/m^2 for about 1 h, in order to generate an additional degradation product 3,6-epoxy

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								vinorelbine having a relative retention time of about 0.8.
POWDERED BLACK PEPPER EXTRACT	DEFINITION	*USP36–NF31*	1365	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 5: Change It contains NLT 90.0% and NMT 110.0% of the labeled amount of piperine. to: It contains NLT 90.0% and NMT 110.0% of the labeled amount of piperine, calculated on the dried basis.
POLYVINYL ACETATE PHTHALATE	IM PURITIES/*Free Phthalic Acid*	*USP36–NF31*	2168	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 1 of *Sample solution*: Change 6 mg/mL of polyvinyl acetate to: 6 mg/mL of polyvinyl acetate phthalate

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DILTIAZEM HYDROCHLORIDE ORAL SUSPENSION	ASSAY/ *Procedure*	*USP36–NF31*	3263	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 6 of *Sample solution*: Change Pipet 1.0 mL of the sample solution to: Pipet 1.0 mL of the sample
IFOSFAMIDE	*Chloroform-insoluble phosphorus*	*USP35–NF30*	3477	29-Mar-2013	1-Apr-2013	*USP37–NF32*	*USP37–NF32*	Line 18 of *Test preparation*: Change ammonium hydroxide solution. to: ammonium hydroxide.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29